Cargando…

The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats

Glycyrrhizinic acid (GL) is clinically applied to treat liver injury, and the bioavailability of orally administered GL is closely related to the gut microbiota. Therefore, the dysbiosis of gut flora in liver injury could significantly influence GL bioavailability. Still, less is known about the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huifang, Wang, Jing, Fu, Yifan, Zhu, Ke, Dong, Zhiling, Shan, Jinjun, Di, Liuqing, Jiang, Shu, Yuan, Tianjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782010/
https://www.ncbi.nlm.nih.gov/pubmed/36558437
http://dx.doi.org/10.3390/nu14245278
_version_ 1784857221773918208
author Li, Huifang
Wang, Jing
Fu, Yifan
Zhu, Ke
Dong, Zhiling
Shan, Jinjun
Di, Liuqing
Jiang, Shu
Yuan, Tianjie
author_facet Li, Huifang
Wang, Jing
Fu, Yifan
Zhu, Ke
Dong, Zhiling
Shan, Jinjun
Di, Liuqing
Jiang, Shu
Yuan, Tianjie
author_sort Li, Huifang
collection PubMed
description Glycyrrhizinic acid (GL) is clinically applied to treat liver injury, and the bioavailability of orally administered GL is closely related to the gut microbiota. Therefore, the dysbiosis of gut flora in liver injury could significantly influence GL bioavailability. Still, less is known about the impact of probiotic supplementation on the bio-absorption process of oral medication, especially under a pathological state. Herein, probiotic L. rhamnosus R0011 (R0011) with a high viability in the harsh gastrointestinal environment was selected, and the effect of R0011 on the GL bioavailability in rats was investigated. Four groups of rats (n = 6 per group) were included: the normal group (N group), the normal group supplemented with R0011 (NLGG group), CCl4-induced chronic liver injury model (M group), and the model group supplemented with R0011 (MLGG group). Our results showed that liver injury was successfully induced in the M and MLGG groups via an intraperitoneal injection of 50% (v/v) CCl4 solution. Healthy rats supplemented with R0011 could increase the bioavailability of GL by 1.4-fold compared with the normal group by plasma pharmacokinetic analysis. Moreover, the GL bioavailability of MLGG group was significantly increased by 4.5-fold compared with the model group. R0011 directly improved gut microbial glucuronidase and downregulated the host intestinal drug transporter gene expression of multidrug resistance protein 2 (MRP2). More critically, R0011 restored the gut microbiota composition and regulated the metabolic function, significantly enhancing the microbial tryptophan metabolic pathway compared with the pathological state, which may indirectly promote the bioavailability of GL. Overall, these data may provide possible strategies by which to address the low bioavailability of traditional medicine through probiotic intervention.
format Online
Article
Text
id pubmed-9782010
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97820102022-12-24 The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats Li, Huifang Wang, Jing Fu, Yifan Zhu, Ke Dong, Zhiling Shan, Jinjun Di, Liuqing Jiang, Shu Yuan, Tianjie Nutrients Article Glycyrrhizinic acid (GL) is clinically applied to treat liver injury, and the bioavailability of orally administered GL is closely related to the gut microbiota. Therefore, the dysbiosis of gut flora in liver injury could significantly influence GL bioavailability. Still, less is known about the impact of probiotic supplementation on the bio-absorption process of oral medication, especially under a pathological state. Herein, probiotic L. rhamnosus R0011 (R0011) with a high viability in the harsh gastrointestinal environment was selected, and the effect of R0011 on the GL bioavailability in rats was investigated. Four groups of rats (n = 6 per group) were included: the normal group (N group), the normal group supplemented with R0011 (NLGG group), CCl4-induced chronic liver injury model (M group), and the model group supplemented with R0011 (MLGG group). Our results showed that liver injury was successfully induced in the M and MLGG groups via an intraperitoneal injection of 50% (v/v) CCl4 solution. Healthy rats supplemented with R0011 could increase the bioavailability of GL by 1.4-fold compared with the normal group by plasma pharmacokinetic analysis. Moreover, the GL bioavailability of MLGG group was significantly increased by 4.5-fold compared with the model group. R0011 directly improved gut microbial glucuronidase and downregulated the host intestinal drug transporter gene expression of multidrug resistance protein 2 (MRP2). More critically, R0011 restored the gut microbiota composition and regulated the metabolic function, significantly enhancing the microbial tryptophan metabolic pathway compared with the pathological state, which may indirectly promote the bioavailability of GL. Overall, these data may provide possible strategies by which to address the low bioavailability of traditional medicine through probiotic intervention. MDPI 2022-12-11 /pmc/articles/PMC9782010/ /pubmed/36558437 http://dx.doi.org/10.3390/nu14245278 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Huifang
Wang, Jing
Fu, Yifan
Zhu, Ke
Dong, Zhiling
Shan, Jinjun
Di, Liuqing
Jiang, Shu
Yuan, Tianjie
The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title_full The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title_fullStr The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title_full_unstemmed The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title_short The Bioavailability of Glycyrrhizinic Acid Was Enhanced by Probiotic Lactobacillus rhamnosus R0011 Supplementation in Liver Fibrosis Rats
title_sort bioavailability of glycyrrhizinic acid was enhanced by probiotic lactobacillus rhamnosus r0011 supplementation in liver fibrosis rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782010/
https://www.ncbi.nlm.nih.gov/pubmed/36558437
http://dx.doi.org/10.3390/nu14245278
work_keys_str_mv AT lihuifang thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT wangjing thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT fuyifan thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT zhuke thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT dongzhiling thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT shanjinjun thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT diliuqing thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT jiangshu thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT yuantianjie thebioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT lihuifang bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT wangjing bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT fuyifan bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT zhuke bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT dongzhiling bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT shanjinjun bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT diliuqing bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT jiangshu bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats
AT yuantianjie bioavailabilityofglycyrrhizinicacidwasenhancedbyprobioticlactobacillusrhamnosusr0011supplementationinliverfibrosisrats